Peer-reviewed
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
Leena Gandhi, Victoria Bray, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell, Susanna Y-S Cheng, Helge G Bischoff, Nir Peled, Francesco Grossi, Ross R Jennens, Martin Reck, Rina Hui, Edward B Garon, Michael Boyer, Belén Rubio-Viqueira, Silvia Novello, Takayasu Kurata, Jhanelle E Gray, John Vida, Ziwen Wei, Jing Yang, Harry Raftopoulos, M Catherine Pietanza, Marina C Garassino, Baerin Ben Houghton, George Kannourakis, Ritwik Pandey, Otto Burghuber, Sylvia Hartl, Bernd Lamprecht, Horst Olschewski, Kathrin Philipp-Abbrederis, Michael Reiter, Michael Schumacher, Michael Studnicka, Marc Lambrechts, Sebahat Ocak, Nathalie Aucoin, Vincent Castonguay, Giovanna Speranza, Andrew Robinson, Stephanie Snow, Jens Benn Soerensen, Karin Holmskov Holmskov Hansen
First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment of choice. The addition of pembrolizumab to chemotherapy resulted in significantly higher rates of response and longer progression-free survival than chemotherapy alone in a phase 2 trial
Article, 2018